Jump to content

Macrophage

From Wikipedia, the free encyclopedia
(Redirected from MΦ)

For the ecological classification, see Macrophage (ecology).

Macrophage
Cytology of a macrophage with typical features. Wright stain.
Details
Pronunciation/ˈmakrə(ʊ)feɪdʒ/
SystemImmune system
FunctionPhagocytosis
Identifiers
Latinmacrophagocytus
Acronym(s)Mφ, MΦ
MeSHD008264
THH2.00.03.0.01007
FMA63261
Anatomical terms of microanatomy

Macrophages (/ˈmækroʊfeɪdʒ/; abbreviated Mφ, MΦ or MP) are a type of white blood cell of the innate immune system that engulf and digest pathogens, such as cancer cells, microbes, cellular debris, and foreign substances, which do not have proteins that are specific to healthy body cells on their surface.[1][2] This process is called phagocytosis, which acts to defend the host against infection and injury.[3]

Macrophages are found in essentially all tissues,[4] where they patrol for potential pathogens by amoeboid movement. They take various forms (with various names) throughout the body (e.g., histiocytes, Kupffer cells, alveolar macrophages, microglia, and others), but all are part of the mononuclear phagocyte system. Besides phagocytosis, they play a critical role in nonspecific defense (innate immunity) and also help initiate specific defense mechanisms (adaptive immunity) by recruiting other immune cells such as lymphocytes. For example, they are important as antigen presenters to T cells. In humans, dysfunctional macrophages cause severe diseases such as chronic granulomatous disease that result in frequent infections.

Beyond increasing inflammation and stimulating the immune system, macrophages also play an important anti-inflammatory role and can decrease immune reactions through the release of cytokines. Macrophages that encourage inflammation are called M1 macrophages, whereas those that decrease inflammation and encourage tissue repair are called M2 macrophages.[5] This difference is reflected in their metabolism; M1 macrophages have the unique ability to metabolize arginine to the "killer" molecule nitric oxide, whereas M2 macrophages have the unique ability to metabolize arginine to the "repair" molecule ornithine.[6] However, this dichotomy has been recently questioned as further complexity has been discovered.[7]

Human macrophages are about 21 micrometres (0.00083 in) in diameter[8] and are produced by the differentiation of monocytes in tissues. They can be identified using flow cytometry or immunohistochemical staining by their specific expression of proteins such as CD14, CD40, CD11b, CD64, F4/80 (mice)/EMR1 (human), lysozyme M, MAC-1/MAC-3 and CD68.[9]

Macrophages were first discovered and named by Élie Metchnikoff, a Russian Empire zoologist, in 1884.[10][11]

Structure

[edit]

Types

[edit]
Main article: Mononuclear phagocyte system
"Macrophage activation" redirects here. For the signal, see Macrophage-activating factor. For the disease syndrome, see Macrophage activation syndrome.
Drawing of a macrophage when fixed and stained by giemsa dye

A majority of macrophages are stationed at strategic points where microbial invasion or accumulation of foreign particles is likely to occur. These cells together as a group are known as the mononuclear phagocyte system and were previously known as the reticuloendothelial system. Each type of macrophage, determined by its location, has a specific name:

Cell Name Anatomical Location
Adipose tissue macrophages Adipose tissue (fat)
Monocytes Bone marrow / blood
Kupffer cells Liver
Sinus histiocytes Lymph nodes
Alveolar macrophages (dust cells) Pulmonary alveoli
Tissue macrophages (histiocytes) leading to giant cells Connective tissue
Microglia Central nervous system
Hofbauer cells Placenta
Intraglomerular mesangial cells[12] Kidney
Osteoclasts [13] Bone
Langerhans cells Skin
Epithelioid cells Granulomas
Red pulp macrophages (sinusoidal lining cells) Red pulp of spleen
Peritoneal macrophages Peritoneal cavity
perivascular Macrophages[14] closely associated with blood vessels

Investigations concerning Kupffer cells are hampered because in humans, Kupffer cells are only accessible for immunohistochemical analysis from biopsies or autopsies. From rats and mice, they are difficult to isolate, and after purification, only approximately 5 million cells can be obtained from one mouse.

Macrophages can express paracrine functions within organs that are specific to the function of that organ. In the testis, for example, macrophages have been shown to be able to interact with Leydig cells by secreting 25-hydroxycholesterol, an oxysterol that can be converted to testosterone by neighbouring Leydig cells.[15] Also, testicular macrophages may participate in creating an immune privileged environment in the testis, and in mediating infertility during inflammation of the testis.

Cardiac resident macrophages participate in electrical conduction via gap junction communication with cardiac myocytes.[16]

Macrophages can be classified on basis of the fundamental function and activation. According to this grouping, there are classically activated (M1) macrophages, wound-healing macrophages (also known as alternatively-activated (M2) macrophages), and regulatory macrophages (Mregs).[17]

Development

[edit]

Macrophages that reside in adult healthy tissues either derive from circulating monocytes or are established before birth and then maintained during adult life independently of monocytes.[18][19] By contrast, most of the macrophages that accumulate at diseased sites typically derive from circulating monocytes.[20] Leukocyte extravasation describes monocyte entry into damaged tissue through the endothelium of blood vessels as they become macrophages. Monocytes are attracted to a damaged site by chemical substances through chemotaxis, triggered by a range of stimuli including damaged cells, pathogens and cytokines released by macrophages already at the site. At some sites such as the testis, macrophages have been shown to populate the organ through proliferation.[21] Unlike short-lived neutrophils, macrophages survive longer in the body, up to several months.

Function

[edit]
Steps of a macrophage ingesting a pathogen:
a. Ingestion through phagocytosis, a phagosome is formed
b. The fusion of lysosomes with the phagosome creates a phagolysosome; the pathogen is broken down by enzymes
c. Waste material is expelled or assimilated (the latter not pictured)
Parts:
1. Pathogens
2. Phagosome
3. Lysosomes
4. Waste material
5. Cytoplasm
6. Cell membrane

Phagocytosis

[edit]
Main article: Phagocytosis

Macrophages are professional phagocytes and are highly specialized in removal of dying or dead cells and cellular debris. This role is important in chronic inflammation, as the early stages of inflammation are dominated by neutrophils, which are ingested by macrophages if they come of age (see CD31 for a description of this process).[22]

The neutrophils are at first attracted to a site, where they perform their function and die, before they or their neutrophil extracellular traps are phagocytized by the macrophages.[22][23] When at the site, the first wave of neutrophils, after the process of aging and after the first 48 hours, stimulate the appearance of the macrophages whereby these macrophages will then ingest the aged neutrophils.[22]

The removal of dying cells is, to a greater extent, handled by fixed macrophages, which will stay at strategic locations such as the lungs, liver, neural tissue, bone, spleen and connective tissue, ingesting foreign materials such as pathogens and recruiting additional macrophages if needed.[24]

When a macrophage ingests a pathogen, the pathogen becomes trapped in a phagosome, which then fuses with a lysosome. Within the phagolysosome, enzymes and toxic peroxides digest the pathogen. However, some bacteria, such as Mycobacterium tuberculosis, have become resistant to these methods of digestion. Typhoidal Salmonellae induce their own phagocytosis by host macrophages in vivo, and inhibit digestion by lysosomal action, thereby using macrophages for their own replication and causing macrophage apoptosis.[25] Macrophages can digest more than 100 bacteria before they finally die due to their own digestive compounds.

Role in innate immune response

[edit]

When a pathogen invades, tissue resident macrophages are among the first cells to respond.[26] Two of the main roles of the tissue resident macrophages are to phagocytose incoming antigen and to secrete proinflammatory cytokines that induce inflammation and recruit other immune cells to the site.[27]

Phagocytosis of pathogens

[edit]
Gram stain of a macrophage with ingested S. epidermidis bacteria, seen as purple granules within its cytoplasm.

Macrophages can internalize antigens through receptor-mediated phagocytosis.[28] Macrophages have a wide variety of pattern recognition receptors (PRRs) that can recognize microbe-associated molecular patterns (MAMPs) from pathogens. Many PRRs, such as toll-like receptors (TLRs), scavenger receptors (SRs), C-type lectin receptors, among others, recognize pathogens for phagocytosis.[28] Macrophages can also recognize pathogens for phagocytosis indirectly through opsonins, which are molecules that attach to pathogens and mark them for phagocytosis.[29] Opsonins can cause a stronger adhesion between the macrophage and pathogen during phagocytosis, hence opsonins tend to enhance macrophages’ phagocytic activity.[30] Both complement proteins and antibodies can bind to antigens and opsonize them. Macrophages have complement receptor 1 (CR1) and 3 (CR3) that recognize pathogen-bound complement proteins C3b and iC3b, respectively, as well as fragment crystallizable γ receptors (FcγRs) that recognize the fragment crystallizable (Fc) region of antigen-bound immunoglobulin G (IgG) antibodies.[29][31] When phagocytosing and digesting pathogens, macrophages go through a respiratory burst where more oxygen is consumed to supply the energy required for producing reactive oxygen species (ROS) and other antimicrobial molecules that digest the consumed pathogens.[27][32]

Cytokine secretion

[edit]

Recognition of MAMPs by PRRs can activate tissue resident macrophages to secrete proinflammatory cytokines that recruit other immune cells. Among the PRRs, TLRs play a major role in signal transduction leading to cytokine production.[28] The binding of MAMPs to TLR triggers a series of downstream events that eventually activates transcription factor NF-κB and results in transcription of the genes for several proinflammatory cytokines, including IL-1β, IL-6, TNF-α, IL-12B, and type I interferons such as IFN-α and IFN-β.[33] Systemically, IL-1β, IL-6, and TNF-α induce fever and initiate the acute phase response in which the liver secretes acute phase proteins.[26][27][34] Locally, IL-1β and TNF-α cause vasodilation, where the gaps between blood vessel epithelial cells widen, and upregulation of cell surface adhesion molecules on epithelial cells to induce leukocyte extravasation.[26][27]

Neutrophils are among the first immune cells recruited by macrophages to exit the blood via extravasation and arrive at the infection site.[34] Macrophages secrete many chemokines such as CXCL1, CXCL2, and CXCL8 (IL-8) that attract neutrophils to the site of infection.[26][34] After neutrophils have finished phagocytosing and clearing the antigen at the end of the immune response, they undergo apoptosis, and macrophages are recruited from blood monocytes to help clear apoptotic debris.[35]

Macrophages also recruit other immune cells such as monocytes, dendritic cells, natural killer cells, basophils, eosinophils, and T cells through chemokines such as CCL2, CCL4, CCL5, CXCL8, CXCL9, CXCL10, and CXCL11.[26][34] Along with dendritic cells, macrophages help activate natural killer (NK) cells through secretion of type I interferons (IFN-α and IFN-β) and IL-12. IL-12 acts with IL-18 to stimulate the production of proinflammatory cytokine interferon gamma (IFN-γ) by NK cells, which serves as an important source of IFN-γ before the adaptive immune system is activated.[34][36] IFN-γ enhances the innate immune response by inducing a more aggressive phenotype in macrophages, allowing macrophages to more efficiently kill pathogens.[34]

Some of the T cell chemoattractants secreted by macrophages include CCL5, CXCL9, CXCL10, and CXCL11.[26]

Role in adaptive immunity

[edit]
A macrophage stretching its "arms" (filopodia)[37] to engulf two particles, possibly pathogens, in a mouse (trypan blue exclusion staining).

Interactions with CD4+ T Helper Cells

[edit]

Macrophages are professional antigen presenting cells (APC), meaning they can present peptides from phagocytosed antigens on major histocompatibility complex (MHC) II molecules on their cell surface for T helper cells.[38] Macrophages are not primary activators of naïve T helper cells that have never been previously activated since tissue resident macrophages do not travel to the lymph nodes where naïve T helper cells reside.[39][40] Although macrophages are also found in secondary lymphoid organs like the lymph nodes, they do not reside in T cell zones and are not effective at activating naïve T helper cells.[39] The macrophages in lymphoid tissues are more involved in ingesting antigens and preventing them from entering the blood, as well as taking up debris from apoptotic lymphocytes.[39][41] Therefore, macrophages interact mostly with previously activated T helper cells that have left the lymph node and arrived at the site of infection or with tissue resident memory T cells.[40]

Macrophages supply both signals required for T helper cell activation: 1) Macrophages present antigen peptide-bound MHC class II molecule to be recognized by the corresponding T cell receptor (TCR), and 2) recognition of pathogens by PRRs induce macrophages to upregulate the co-stimulatory molecules CD80 and CD86 (also known as B7) that binds to CD28 on T helper cells to supply the co-stimulatory signal.[34][38] These interactions allow T helper cells to achieve full effector function and provide T helper cells with continued survival and differentiation signals preventing them from undergoing apoptosis due to lack of TCR signaling.[38] For example, IL-2 signaling in T cells upregulates the expression of anti-apoptotic protein Bcl-2, but T cell production of IL-2 and the high-affinity IL-2 receptor IL-2RA both require continued signal from TCR recognition of MHC-bound antigen.[34][42]

Activation

[edit]

Macrophages can achieve different activation phenotypes through interactions with different subsets of T helper cells, such as TH1 and TH2.[17] Although there is a broad spectrum of macrophage activation phenotypes, there are two major phenotypes that are commonly acknowledged.[17] They are the classically activated macrophages, or M1 macrophages, and the alternatively activated macrophages, or M2 macrophages. M1 macrophages are proinflammatory, while M2 macrophages are mostly anti-inflammatory.[17]

Classical
[edit]

TH1 cells play an important role in classical macrophage activation as part of type 1 immune response against intracellular pathogens (such as intracellular bacteria) that can survive and replicate inside host cells, especially those pathogens that replicate even after being phagocytosed by macrophages.[43] After the TCR of TH1 cells recognize specific antigen peptide-bound MHC class II molecules on macrophages, TH1 cells 1) secrete IFN-γ and 2) upregulate the expression of CD40 ligand (CD40L), which binds to CD40 on macrophages.[44][34] These 2 signals activate the macrophages and enhance their ability to kill intracellular pathogens through increased production of antimicrobial molecules such as nitric oxide (NO) and superoxide (O2-).[26][34] This enhancement of macrophages' antimicrobial ability by TH1 cells is known as classical macrophage activation, and the activated macrophages are known as classically activated macrophages, or M1 macrophages. The M1 macrophages in turn upregulate B7 molecules and antigen presentation through MHC class II molecules to provide signals that sustain T cell help.[44] The activation of TH1 and M1 macrophage is a positive feedback loop, with IFN-γ from TH1 cells upregulating CD40 expression on macrophages; the interaction between CD40 on the macrophages and CD40L on T cells activate macrophages to secrete IL-12; and IL-12 promotes more IFN-γ secretion from TH1 cells.[34][44] The initial contact between macrophage antigen-bound MHC II and TCR serves as the contact point between the two cells where most of the IFN-γ secretion and CD-40L on T cells concentrate to, so only macrophages directly interacting with TH1 cells are likely to be activated.[34]

In addition to activating M1 macrophages, TH1 cells express Fas ligand (FasL) and lymphotoxin beta (LT-β) to help kill chronically infected macrophages that can no longer kill pathogens.[34] The killing of chronically infected macrophages release pathogens to the extracellular space that can then be killed by other activated macrophages.[34] TH1 cells also help recruit more monocytes, the precursor to macrophages, to the infection site. TH1 secretion TNF-α and LT-α to make blood vessels easier for monocytes to bind to and exit.[34] TH1 secretion of CCL2 as a chemoattractant for monocytes. IL-3 and GM-CSF released by TH1 cells stimulate more monocyte production in the bone marrow.[34]

When intracellular pathogens cannot be eliminated, such as in the case of Mycobacterium tuberculosis, the pathogen is contained through the formation of granuloma, an aggregation of infected macrophages surrounded by activated T cells.[45] The macrophages bordering the activated lymphocytes often fuse to form multinucleated giant cells that appear to have increased antimicrobial ability due to their proximity to TH1 cells, but over time, the cells in the center start to die and form necrotic tissue.[40][45]

Alternative
[edit]

TH2 cells play an important role in alternative macrophage activation as part of type 2 immune response against large extracellular pathogens like helminths.[34][46] TH2 cells secrete IL-4 and IL-13, which activate macrophages to become M2 macrophages, also known as alternatively activated macrophages.[46][47] M2 macrophages express arginase-1, an enzyme that converts arginine to ornithine and urea.[46] Ornithine help increase smooth muscle contraction to expel the worm and also participates in tissue and wound repair. Ornithine can be further metabolized to proline, which is essential for synthesizing collagen.[46] M2 macrophages can also decrease inflammation by producing IL-1 receptor antagonist (IL-1RA) and IL-1 receptors that do not lead to downstream inflammatory signaling (IL-1RII).[34][48]

Interactions with CD8+ cytotoxic t cells

[edit]

Another part of the adaptive immunity activation involves stimulating CD8+ via cross presentation of antigens peptides on MHC class I molecules. Studies have shown that proinflammatory macrophages are capable of cross presentation of antigens on MHC class I molecules, but whether macrophage cross-presentation plays a role in naïve or memory CD8+ T cell activation is still unclear.[27][49][41]

Interactions with B cells

[edit]

Macrophages have been shown to secrete cytokines BAFF and APRIL, which are important for plasma cell isotype switching. APRIL and IL-6 secreted by macrophage precursors in the bone marrow help maintain survival of plasma cells homed to the bone marrow.[50]

Subtypes

[edit]
Siderophage
Anthracotic macrophage
Pigmented macrophages can be classified by the pigment type, such as for alveolar macrophages shown above (white arrows). A "siderophage" contains hemosiderin (also shown by black arrow in left image), while anthracotic macrophages result from coal dust inhalation (and also long-term air pollution).[51] H&E stain.

There are several activated forms of macrophages.[17] In spite of a spectrum of ways to activate macrophages, there are two main groups designated M1 and M2. M1 macrophages: as mentioned earlier (previously referred to as classically activated macrophages),[52] M1 "killer" macrophages are activated by LPS and IFN-gamma, and secrete high levels of IL-12 and low levels of IL-10. M1 macrophages have pro-inflammatory, bactericidal, and phagocytic functions.[53] In contrast, the M2 "repair" designation (also referred to as alternatively activated macrophages) broadly refers to macrophages that function in constructive processes like wound healing and tissue repair, and those that turn off damaging immune system activation by producing anti-inflammatory cytokines like IL-10. M2 is the phenotype of resident tissue macrophages, and can be further elevated by IL-4. M2 macrophages produce high levels of IL-10, TGF-beta and low levels of IL-12. Tumor-associated macrophages are mainly of the M2 phenotype, and seem to actively promote tumor growth.[54]

Macrophages exist in a variety of phenotypes which are determined by the role they play in wound maturation. Phenotypes can be predominantly separated into two major categories; M1 and M2. M1 macrophages are the dominating phenotype observed in the early stages of inflammation and are activated by four key mediators: interferon-γ (IFN-γ), tumor necrosis factor (TNF), and damage associated molecular patterns (DAMPs). These mediator molecules create a pro-inflammatory response that in return produce pro-inflammatory cytokines like Interleukin-6 and TNF. Unlike M1 macrophages, M2 macrophages secrete an anti-inflammatory response via the addition of Interleukin-4 or Interleukin-13. They also play a role in wound healing and are needed for revascularization and reepithelialization. M2 macrophages are divided into four major types based on their roles: M2a, M2b, M2c, and M2d. How M2 phenotypes are determined is still up for discussion but studies have shown that their environment allows them to adjust to whichever phenotype is most appropriate to efficiently heal the wound.[53]

M2 macrophages are needed for vascular stability. They produce vascular endothelial growth factor-A and TGF-β1.[53] There is a phenotype shift from M1 to M2 macrophages in acute wounds, however this shift is impaired for chronic wounds. This dysregulation results in insufficient M2 macrophages and its corresponding growth factors that aid in wound repair. With a lack of these growth factors/anti-inflammatory cytokines and an overabundance of pro-inflammatory cytokines from M1 macrophages chronic wounds are unable to heal in a timely manner. Normally, after neutrophils eat debris/pathogens they perform apoptosis and are removed. At this point, inflammation is not needed and M1 undergoes a switch to M2 (anti-inflammatory). However, dysregulation occurs as the M1 macrophages are unable/do not phagocytose neutrophils that have undergone apoptosis leading to increased macrophage migration and inflammation.[53]

Both M1 and M2 macrophages play a role in promotion of atherosclerosis. M1 macrophages promote atherosclerosis by inflammation. M2 macrophages can remove cholesterol from blood vessels, but when the cholesterol is oxidized, the M2 macrophages become apoptotic foam cells contributing to the atheromatous plaque of atherosclerosis.[55][56]

Role in muscle regeneration

[edit]

The first step to understanding the importance of macrophages in muscle repair, growth, and regeneration is that there are two "waves" of macrophages with the onset of damageable muscle use– subpopulations that do and do not directly have an influence on repairing muscle. The initial wave is a phagocytic population that comes along during periods of increased muscle use that are sufficient to cause muscle membrane lysis and membrane inflammation, which can enter and degrade the contents of injured muscle fibers.[57][58][59] These early-invading, phagocytic macrophages reach their highest concentration about 24 hours following the onset of some form of muscle cell injury or reloading.[60] Their concentration rapidly declines after 48 hours.[58] The second group is the non-phagocytic types that are distributed near regenerative fibers. These peak between two and four days and remain elevated for several days during while muscle tissue is rebuilding.[58] The first subpopulation has no direct benefit to repairing muscle, while the second non-phagocytic group does.

It is thought that macrophages release soluble substances that influence the proliferation, differentiation, growth, repair, and regeneration of muscle, but at this time the factor that is produced to mediate these effects is unknown.[60] It is known that macrophages' involvement in promoting tissue repair is not muscle specific; they accumulate in numerous tissues during the healing process phase following injury.[61]

Role in wound healing

[edit]

Macrophages are essential for wound healing.[62] They replace polymorphonuclear neutrophils as the predominant cells in the wound by day two after injury.[63] Attracted to the wound site by growth factors released by platelets and other cells, monocytes from the bloodstream enter the area through blood vessel walls.[64] Numbers of monocytes in the wound peak one to one and a half days after the injury occurs. Once they are in the wound site, monocytes mature into macrophages. The spleen contains half the body's monocytes in reserve ready to be deployed to injured tissue.[65][66]

The macrophage's main role is to phagocytize bacteria and damaged tissue,[62] and they also debride damaged tissue by releasing proteases.[67] Macrophages also secrete a number of factors such as growth factors and other cytokines, especially during the third and fourth post-wound days. These factors attract cells involved in the proliferation stage of healing to the area.[68] Macrophages may also restrain the contraction phase.[69] Macrophages are stimulated by the low oxygen content of their surroundings to produce factors that induce and speed angiogenesis[70] and they also stimulate cells that re-epithelialize the wound, create granulation tissue, and lay down a new extracellular matrix.[71][better source needed] By secreting these factors, macrophages contribute to pushing the wound healing process into the next phase.

Role in limb regeneration

[edit]

Scientists have elucidated that as well as eating up material debris, macrophages are involved in the typical limb regeneration in the salamander.[72][73] They found that removing the macrophages from a salamander resulted in failure of limb regeneration and a scarring response.[72][73]

Role in iron homeostasis

[edit]
Main article: Human iron metabolism

As described above, macrophages play a key role in removing dying or dead cells and cellular debris. Erythrocytes have a lifespan on average of 120 days and so are constantly being destroyed by macrophages in the spleen and liver. Macrophages will also engulf macromolecules, and so play a key role in the pharmacokinetics of parenteral irons.[citation needed]

The iron that is released from the haemoglobin is either stored internally in ferritin or is released into the circulation via ferroportin. In cases where systemic iron levels are raised, or where inflammation is present, raised levels of hepcidin act on macrophage ferroportin channels, leading to iron remaining within the macrophages.[citation needed]

Role in pigment retainment

[edit]
Melanophage. H&E stain.

Melanophages are a subset of tissue-resident macrophages able to absorb pigment, either native to the organism or exogenous (such as tattoos), from extracellular space. In contrast to dendritic juncional melanocytes, which synthesize melanosomes and contain various stages of their development, the melanophages only accumulate phagocytosed melanin in lysosome-like phagosomes.[74][75] This occurs repeatedly as the pigment from dead dermal macrophages is phagocytosed by their successors, preserving the tattoo in the same place.[76]

Role in tissue homeostasis

[edit]

Every tissue harbors its own specialized population of resident macrophages, which entertain reciprocal interconnections with the stroma and functional tissue.[77][78] These resident macrophages are sessile (non-migratory), provide essential growth factors to support the physiological function of the tissue (e.g. macrophage-neuronal crosstalk in the guts),[79] and can actively protect the tissue from inflammatory damage.[80]

Nerve-associated macrophages

[edit]

Nerve-associated macrophages or NAMs are those tissue-resident macrophages that are associated with nerves. Some of them are known to have an elongated morphology of up to 200μm [81]

Clinical significance

[edit]

Due to their role in phagocytosis, macrophages are involved in many diseases of the immune system. For example, they participate in the formation of granulomas, inflammatory lesions that may be caused by a large number of diseases. Some disorders, mostly rare, of ineffective phagocytosis and macrophage function have been described, for example.[82]

As a host for intracellular pathogens

[edit]

In their role as a phagocytic immune cell macrophages are responsible for engulfing pathogens to destroy them. Some pathogens subvert this process and instead live inside the macrophage. This provides an environment in which the pathogen is hidden from the immune system and allows it to replicate.[citation needed]

Diseases with this type of behaviour include tuberculosis (caused by Mycobacterium tuberculosis) and leishmaniasis (caused by Leishmania species).[citation needed]

In order to minimize the possibility of becoming the host of an intracellular bacteria, macrophages have evolved defense mechanisms such as induction of nitric oxide and reactive oxygen intermediates,[83] which are toxic to microbes. Macrophages have also evolved the ability to restrict the microbe's nutrient supply and induce autophagy.[84]

Tuberculosis

[edit]

Once engulfed by a macrophage, the causative agent of tuberculosis, Mycobacterium tuberculosis,[85] avoids cellular defenses and uses the cell to replicate. Recent evidence suggests that in response to the pulmonary infection of Mycobacterium tuberculosis, the peripheral macrophages matures into M1 phenotype. Macrophage M1 phenotype is characterized by increased secretion of pro-inflammatory cytokines (IL-1β, TNF-α, and IL-6) and increased glycolytic activities essential for clearance of infection.[1]

Leishmaniasis

[edit]

Upon phagocytosis by a macrophage, the Leishmania parasite finds itself in a phagocytic vacuole. Under normal circumstances, this phagocytic vacuole would develop into a lysosome and its contents would be digested. Leishmania alter this process and avoid being destroyed; instead, they make a home inside the vacuole.[citation needed]

Chikungunya

[edit]

Infection of macrophages in joints is associated with local inflammation during and after the acute phase of Chikungunya (caused by CHIKV or Chikungunya virus).[86]

Others

[edit]

Adenovirus (most common cause of pink eye) can remain latent in a host macrophage, with continued viral shedding 6–18 months after initial infection.[citation needed]

Brucella spp. can remain latent in a macrophage via inhibition of phagosome–lysosome fusion; causes brucellosis (undulant fever).[citation needed]

Legionella pneumophila, the causative agent of Legionnaires' disease, also establishes residence within macrophages.[citation needed]

Heart disease

[edit]

Macrophages are the predominant cells involved in creating the progressive plaque lesions of atherosclerosis.[87]

Focal recruitment of macrophages occurs after the onset of acute myocardial infarction. These macrophages function to remove debris, apoptotic cells and to prepare for tissue regeneration.[88] Macrophages protect against ischemia-induced ventricular tachycardia in hypokalemic mice.[89]

HIV infection

[edit]

Macrophages also play a role in human immunodeficiency virus (HIV) infection. Like T cells, macrophages can be infected with HIV, and even become a reservoir of ongoing virus replication throughout the body. HIV can enter the macrophage through binding of gp120 to CD4 and second membrane receptor, CCR5 (a chemokine receptor). Both circulating monocytes and macrophages serve as a reservoir for the virus.[90] Macrophages are better able to resist infection by HIV-1 than CD4+ T cells, although susceptibility to HIV infection differs among macrophage subtypes.[91]

Cancer

[edit]

Macrophages can contribute to tumor growth and progression by promoting tumor cell proliferation and invasion, fostering tumor angiogenesis and suppressing antitumor immune cells.[92][93] Inflammatory compounds, such as tumor necrosis factor (TNF)-alpha released by the macrophages activate the gene switch nuclear factor-kappa B. NF-κB then enters the nucleus of a tumor cell and turns on production of proteins that stop apoptosis and promote cell proliferation and inflammation.[94] Moreover, macrophages serve as a source for many pro-angiogenic factors including vascular endothelial factor (VEGF), tumor necrosis factor-alpha (TNF-alpha), macrophage colony-stimulating factor (M-CSF/CSF1) and IL-1 and IL-6,[95] contributing further to the tumor growth.

Macrophages have been shown to infiltrate a number of tumors. Their number correlates with poor prognosis in certain cancers, including cancers of breast, cervix, bladder, brain and prostate.[96][97] Some tumors can also produce factors, including M-CSF/CSF1, MCP-1/CCL2 and Angiotensin II, that trigger the amplification and mobilization of macrophages in tumors.[98][99][100] Additionally, subcapsular sinus macrophages in tumor-draining lymph nodes can suppress cancer progression by containing the spread of tumor-derived materials.[101]

Cancer therapy

[edit]

Experimental studies indicate that macrophages can affect all therapeutic modalities, including surgery, chemotherapy, radiotherapy, immunotherapy and targeted therapy.[93][102][103] Macrophages can influence treatment outcomes both positively and negatively. Macrophages can be protective in different ways: they can remove dead tumor cells (in a process called phagocytosis) following treatments that kill these cells; they can serve as drug depots for some anticancer drugs;[104] they can also be activated by some therapies to promote antitumor immunity.[105] Macrophages can also be deleterious in several ways: for example they can suppress various chemotherapies,[106][107] radiotherapies[108][109] and immunotherapies.[110][111] Because macrophages can regulate tumor progression, therapeutic strategies to reduce the number of these cells, or to manipulate their phenotypes, are currently being tested in cancer patients.[112][113] However, macrophages are also involved in antibody mediated cytotoxicity (ADCC) and this mechanism has been proposed to be important for certain cancer immunotherapy antibodies.[114]

Obesity

[edit]

It has been observed that increased number of pro-inflammatory macrophages within obese adipose tissue contributes to obesity complications including insulin resistance and diabetes type 2.[115]

The modulation of the inflammatory state of adipose tissue macrophages has therefore been considered a possible therapeutic target to treat obesity-related diseases.[116] Although adipose tissue macrophages are subject to anti-inflammatory homeostatic control by sympathetic innervation, experiments using ADRB2 gene knockout mice indicate that this effect is indirectly exerted through the modulation of adipocyte function, and not through direct Beta-2 adrenergic receptor activation, suggesting that adrenergic stimulation of macrophages may be insufficient to impact adipose tissue inflammation or function in obesity.[117]

Within the fat (adipose) tissue of CCR2 deficient mice, there is an increased number of eosinophils, greater alternative macrophage activation, and a propensity towards type 2 cytokine expression. Furthermore, this effect was exaggerated when the mice became obese from a high fat diet.[118] This is partially caused by a phenotype switch of macrophages induced by necrosis of fat cells (adipocytes). In an obese individual some adipocytes burst and undergo necrotic death, which causes the residential M2 macrophages to switch to M1 phenotype. This is one of the causes of a low-grade systemic chronic inflammatory state associated with obesity.[119][120]

Intestinal macrophages

[edit]

Though very similar in structure to tissue macrophages, intestinal macrophages have evolved specific characteristics and functions given their natural environment, which is in the digestive tract. Macrophages and intestinal macrophages have high plasticity causing their phenotype to be altered by their environments.[121] Like macrophages, intestinal macrophages are differentiated monocytes, though intestinal macrophages have to coexist with the microbiome in the intestines. This is a challenge considering the bacteria found in the gut are not recognized as "self" and could be potential targets for phagocytosis by the macrophage.[122]

To prevent the destruction of the gut bacteria, intestinal macrophages have developed key differences compared to other macrophages. Primarily, intestinal macrophages do not induce inflammatory responses. Whereas tissue macrophages release various inflammatory cytokines, such as IL-1, IL-6 and TNF-α, intestinal macrophages do not produce or secrete inflammatory cytokines. This change is directly caused by the intestinal macrophages environment. Surrounding intestinal epithelial cells release TGF-β, which induces the change from proinflammatory macrophage to noninflammatory macrophage.[122]

Even though the inflammatory response is downregulated in intestinal macrophages, phagocytosis is still carried out. There is no drop off in phagocytosis efficiency as intestinal macrophages are able to effectively phagocytize the bacteria,S. typhimurium and E. coli, but intestinal macrophages still do not release cytokines, even after phagocytosis. Also, intestinal macrophages do not express lipopolysaccharide (LPS), IgA, or IgG receptors.[123] The lack of LPS receptors is important for the gut as the intestinal macrophages do not detect the microbe-associated molecular patterns (MAMPS/PAMPS) of the intestinal microbiome. Nor do they express IL-2 and IL-3 growth factor receptors.[122]

Role in disease

[edit]

Intestinal macrophages have been shown to play a role in inflammatory bowel disease (IBD), such as Crohn's disease (CD) and ulcerative colitis (UC). In a healthy gut, intestinal macrophages limit the inflammatory response in the gut, but in a disease-state, intestinal macrophage numbers and diversity are altered. This leads to inflammation of the gut and disease symptoms of IBD. Intestinal macrophages are critical in maintaining gut homeostasis. The presence of inflammation or pathogen alters this homeostasis, and concurrently alters the intestinal macrophages.[124] There has yet to be a determined mechanism for the alteration of the intestinal macrophages by recruitment of new monocytes or changes in the already present intestinal macrophages.[123]

Additionally, a new study reveals macrophages limit iron access to bacteria by releasing extracellular vesicles, improving sepsis outcomes.[125]

Media

[edit]
  • An active J774 macrophage is seen taking up four conidia in a co-operative manner. The J774 cells were treated with 5ng/ml interferon-γ one night before filming with conidia. Observations were made every 30s over a 2.5hr period.
  • Two highly active alveolar macrophages can be seen ingesting conidia. Time lapse is 30s per frame over 2.5hr.

History

[edit]

Macrophages were first discovered late in the 19th century by Élie Metchnikoff.[126]Élie Metchnikoff revolutionized the branch of macrophages by combining philosophical insights and the evolutionary study of life.[127] Later on, Van Furth during the 1960s proposed the idea that circulating blood monocytes in adults allowed for the origin of all tissue macrophages.[128] In recent years, publishing regarding macrophages has led people to believe that multiple resident tissue macrophages are independent of the blood monocytes as it is formed during the embryonic stage of development.[129] Within the 21st century, all the ideas concerning the origin of macrophages (present in tissues) are compiled together to suggest that physiologically complex organisms, form macrophages independently by mechanisms that don't have to depend on the blood monocytes.[130]

See also

[edit]

References

[edit]
  1. ^ a b Mahla RS, Kumar A, Tutill HJ, Krishnaji ST, Sathyamoorthy B, Noursadeghi M, et al. (January 2021). "NIX-mediated mitophagy regulate metabolic reprogramming in phagocytic cells during mycobacterial infection". Tuberculosis. 126 (January): 102046. doi:10.1016/j.tube.2020.102046. PMID 33421909. S2CID 231437641.
  2. ^ "Regenerative Medicine Partnership in Education". Archived from the original on 25 April 2015. Retrieved 7 May 2015.
  3. ^ Nahrendorf M, Hoyer FF, Meerwaldt AE, van Leent MM, Senders ML, Calcagno C, et al. (October 2020). "Imaging Cardiovascular and Lung Macrophages With the Positron Emission Tomography Sensor 64Cu-Macrin in Mice, Rabbits, and Pigs". Circulation: Cardiovascular Imaging. 13 (10): e010586. doi:10.1161/CIRCIMAGING.120.010586. PMC 7583675. PMID 33076700.
  4. ^ Ovchinnikov DA (September 2008). "Macrophages in the embryo and beyond: much more than just giant phagocytes". Genesis. 46 (9): 447–462. doi:10.1002/dvg.20417. PMID 18781633. S2CID 38894501. Macrophages are present essentially in all tissues, beginning with embryonic development and, in addition to their role in host defense and in the clearance of apoptotic cells, are being increasingly recognized for their trophic function and role in regeneration.
  5. ^ Mills CD (2012). "M1 and M2 Macrophages: Oracles of Health and Disease". Critical Reviews in Immunology. 32 (6): 463–488. doi:10.1615/CritRevImmunol.v32.i6.10. PMID 23428224.
  6. ^ Murphy K, Weaver C (2006). Janeway's immunobiology. Garland Science, New York. pp. 464, 904. ISBN 978-0-8153-4551-0.
  7. ^ Ransohoff RM (July 2016). "A polarizing question: do M1 and M2 microglia exist?". Nature Neuroscience. 19 (8): 987–991. doi:10.1038/nn.4338. PMID 27459405. S2CID 27541569.
  8. ^ Krombach F, Münzing S, Allmeling AM, Gerlach JT, Behr J, Dörger M (September 1997). "Cell size of alveolar macrophages: an interspecies comparison". Environmental Health Perspectives. 105 (Suppl 5): 1261–1263. doi:10.2307/3433544. JSTOR 3433544. PMC 1470168. PMID 9400735.
  9. ^ Khazen W, M'bika JP, Tomkiewicz C, Benelli C, Chany C, Achour A, et al. (October 2005). "Expression of macrophage-selective markers in human and rodent adipocytes". FEBS Letters. 579 (25): 5631–5634. doi:10.1016/j.febslet.2005.09.032. PMID 16213494. S2CID 6066984.
  10. ^ Zalkind S (2001). Ilya Mechnikov: His Life and Work. Honolulu, Hawaii: University Press of the Pacific. pp. 78, 210. ISBN 978-0-89875-622-7.
  11. ^ Shapouri-Moghaddam A, Mohammadian S, Vazini H, Taghadosi M, Esmaeili SA, Mardani F, et al. (September 2018). "Macrophage plasticity, polarization, and function in health and disease". Journal of Cellular Physiology. 233 (9): 6425–6440. doi:10.1002/jcp.26429. PMID 29319160. S2CID 3621509.
  12. ^ Lote CJ. Principles of Renal Physiology, 5th edition. Springer. p. 37.
  13. ^ Shirazi S, Ravindran S, Cooper LF (December 2022). "Topography-mediated immunomodulation in osseointegration; Ally or Enemy". Biomaterials. 291: 121903. doi:10.1016/j.biomaterials.2022.121903. PMC 10148651. PMID 36410109.
  14. ^ Siret C, van Lessen M, Bavais J, Jeong HW, Reddy Samawar SK, Kapupara K, et al. (2022). "Deciphering the heterogeneity of the Lyve1+ perivascular macrophages in the mouse brain". Nature Communications. 13 (1): 7366. Bibcode:2022NatCo..13.7366S. doi:10.1038/s41467-022-35166-9. PMC 9712536. PMID 36450771.
  15. ^ Nes WD, Lukyanenko YO, Jia ZH, Quideau S, Howald WN, Pratum TK, et al. (March 2000). "Identification of the lipophilic factor produced by macrophages that stimulates steroidogenesis". Endocrinology. 141 (3): 953–958. doi:10.1210/endo.141.3.7350. PMID 10698170.
  16. ^ Hulsmans M, Clauss S, Xiao L, Aguirre AD, King KR, Hanley A, et al. (April 2017). "Macrophages Facilitate Electrical Conduction in the Heart". Cell. 169 (3): 510–522.e20. doi:10.1016/j.cell.2017.03.050. PMC 5474950. PMID 28431249.
  17. ^ a b c d e Mosser DM, Edwards JP (December 2008). "Exploring the full spectrum of macrophage activation". Nature Reviews. Immunology. 8 (12): 958–969. doi:10.1038/nri2448. PMC 2724991. PMID 19029990.
  18. ^ Perdiguero EG, Geissmann F (January 2016). "The development and maintenance of resident macrophages". Nature Immunology. 17 (1): 2–8. doi:10.1038/ni.3341. PMC 4950995. PMID 26681456.
  19. ^ Ginhoux F, Guilliams M (March 2016). "Tissue-Resident Macrophage Ontogeny and Homeostasis". Immunity. 44 (3): 439–449. doi:10.1016/j.immuni.2016.02.024. PMID 26982352.
  20. ^ Pittet MJ, Nahrendorf M, Swirski FK (June 2014). "The journey from stem cell to macrophage". Annals of the New York Academy of Sciences. 1319 (1): 1–18. Bibcode:2014NYASA1319....1P. doi:10.1111/nyas.12393. PMC 4074243. PMID 24673186.
  21. ^ Wang M, Yang Y, Cansever D, Wang Y, Kantores C, Messiaen S, et al. (January 2021). "Two populations of self-maintaining monocyte-independent macrophages exist in adult epididymis and testis". Proceedings of the National Academy of Sciences of the United States of America. 118 (1): e2013686117. Bibcode:2021PNAS..11813686W. doi:10.1073/pnas.2013686117. PMC 7817195. PMID 33372158.
  22. ^ a b c Eming SA, Krieg T, Davidson JM (March 2007). "Inflammation in wound repair: molecular and cellular mechanisms". The Journal of Investigative Dermatology. 127 (3): 514–25. doi:10.1038/sj.jid.5700701. PMID 17299434. =Monocytes/macrophages. Unless stimuli for neutrophil recruitment persist at the wound site, the neutrophil infiltration ceases after few days, and expended neutrophils are themselves phagocytosed by macrophages, which are present at the wound side within 2 days after injury.
  23. ^ Monteith AJ, Miller JM, Maxwell CN, Chazin WJ, Skaar EP (September 2021). "Neutrophil extracellular traps enhance macrophage killing of bacterial pathogens". Science Advances. 7 (37): eabj2101. Bibcode:2021SciA....7.2101M. doi:10.1126/sciadv.abj2101. PMC 8442908. PMID 34516771.
  24. ^ Verma N, Saraf S (15 November 2017). "A Role of Macrophages: An Overview". Journal of Drug Delivery and Therapeutics. 7 (6): 91–103. doi:10.22270/jddt.v7i6.1521. ISSN 2250-1177.
  25. ^ YashRoy RC (2000). "Hijacking of Macrophages by Salmonella (310r) Through 'Types III' Secretion Like Exocytotic Signalling : A Mechanism for Infection of Chicken Ileum". Indian Journal of Poultry Science. 35 (3): 276–281.
  26. ^ a b c d e f g Arango Duque G, Descoteaux A (7 October 2014). "Macrophage cytokines: involvement in immunity and infectious diseases". Frontiers in Immunology. 5: 491. doi:10.3389/fimmu.2014.00491. PMC 4188125. PMID 25339958.
  27. ^ a b c d e Punt J, Stranford S, Jones P, Owen J (25 May 2018). Kuby Immunology (8th ed.). New York, New York: W. H. Freeman. ISBN 978-1-4641-8978-4.
  28. ^ a b c Fu YL, Harrison RE (29 April 2021). "Microbial Phagocytic Receptors and Their Potential Involvement in Cytokine Induction in Macrophages". Frontiers in Immunology. 12: 662063. doi:10.3389/fimmu.2021.662063. PMC 8117099. PMID 33995386.
  29. ^ a b Hirayama D, Iida T, Nakase H (December 2017). "The Phagocytic Function of Macrophage-Enforcing Innate Immunity and Tissue Homeostasis". International Journal of Molecular Sciences. 19 (1): 92. doi:10.3390/ijms19010092. PMC 5796042. PMID 29286292.
  30. ^ Uribe-Querol E, Rosales C (2 June 2020). "Phagocytosis: Our Current Understanding of a Universal Biological Process". Frontiers in Immunology. 11: 1066. doi:10.3389/fimmu.2020.01066. PMC 7280488. PMID 32582172.
  31. ^ Law SK (1 January 1988). "C3 receptors on macrophages". Journal of Cell Science. Supplement. 9 (Supplement_9): 67–97. doi:10.1242/jcs.1988.Supplement_9.4. PMID 2978518. S2CID 29387085.
  32. ^ Forman HJ, Torres M (December 2002). "Reactive oxygen species and cell signaling: respiratory burst in macrophage signaling". American Journal of Respiratory and Critical Care Medicine. 166 (12 Pt 2): S4–S8. doi:10.1164/rccm.2206007. PMID 12471082. S2CID 22246117.
  33. ^ Liu T, Zhang L, Joo D, Sun SC (14 July 2017). "NF-κB signaling in inflammation". Signal Transduction and Targeted Therapy. 2 (1): 17023–. doi:10.1038/sigtrans.2017.23. PMC 5661633. PMID 29158945.
  34. ^ a b c d e f g h i j k l m n o p q r Murphy K, Weaver C, Berg L (2022). Janeway's Immunobiology (10th ed.). New York, New York: W. W. Norton & Company. ISBN 978-0-393-88487-6.
  35. ^ Eming SA, Krieg T, Davidson JM (March 2007). "Inflammation in wound repair: molecular and cellular mechanisms". The Journal of Investigative Dermatology. 127 (3): 514–525. doi:10.1038/sj.jid.5700701. PMID 17299434.
  36. ^ Mezouar S, Mege JL (July 2020). "Changing the paradigm of IFN-γ at the interface between innate and adaptive immunity: Macrophage-derived IFN-γ". Journal of Leukocyte Biology. 108 (1): 419–426. doi:10.1002/JLB.4MIR0420-619RR. PMID 32531848. S2CID 219622032.
  37. ^ Kress H, Stelzer EH, Holzer D, Buss F, Griffiths G, Rohrbach A (July 2007). "Filopodia act as phagocytic tentacles and pull with discrete steps and a load-dependent velocity". Proceedings of the National Academy of Sciences of the United States of America. 104 (28): 11633–11638. Bibcode:2007PNAS..10411633K. doi:10.1073/pnas.0702449104. PMC 1913848. PMID 17620618.
  38. ^ a b c Guerriero JL (2019). "Macrophages: Their Untold Story in T Cell Activation and Function". International Review of Cell and Molecular Biology. 342. Elsevier: 73–93. doi:10.1016/bs.ircmb.2018.07.001. ISBN 978-0-12-815381-9. PMID 30635094.
  39. ^ a b c Itano AA, Jenkins MK (August 2003). "Antigen presentation to naive CD4 T cells in the lymph node". Nature Immunology. 4 (8): 733–739. doi:10.1038/ni957. PMID 12888794. S2CID 10305140.
  40. ^ a b c Murphy K, Weaver C (2016). Janeway's Immunobiology (9th ed.). New York, New York: Garland Science. pp. 363–364. ISBN 978-0-8153-4505-3.
  41. ^ a b Gray EE, Cyster JG (2012). "Lymph node macrophages". Journal of Innate Immunity. 4 (5–6): 424–436. doi:10.1159/000337007. PMC 3574571. PMID 22488251.
  42. ^ Abbas AK (September 2020). "The Surprising Story of IL-2". The American Journal of Pathology. 190 (9): 1776–1781. doi:10.1016/j.ajpath.2020.05.007. PMID 32828360. S2CID 221280663.
  43. ^ Annunziato F, Romagnani C, Romagnani S (March 2015). "The 3 major types of innate and adaptive cell-mediated effector immunity". The Journal of Allergy and Clinical Immunology. 135 (3): 626–635. doi:10.1016/j.jaci.2014.11.001. PMID 25528359.
  44. ^ a b c Cai H, Zhang Y, Wang J, Gu J (23 June 2021). "Defects in Macrophage Reprogramming in Cancer Therapy: The Negative Impact of PD-L1/PD-1". Frontiers in Immunology. 12: 690869. doi:10.3389/fimmu.2021.690869. PMC 8260839. PMID 34248982.
  45. ^ a b Hilhorst M, Shirai T, Berry G, Goronzy JJ, Weyand CM (2014). "T cell-macrophage interactions and granuloma formation in vasculitis". Frontiers in Immunology. 5: 432. doi:10.3389/fimmu.2014.00432. PMC 4162471. PMID 25309534.
  46. ^ a b c d Rolot M, Dewals BG (2 July 2018). "Macrophage Activation and Functions during Helminth Infection: Recent Advances from the Laboratory Mouse". Journal of Immunology Research. 2018: 2790627. doi:10.1155/2018/2790627. PMC 6051086. PMID 30057915.
  47. ^ Gordon S (January 2003). "Alternative activation of macrophages". Nature Reviews. Immunology. 3 (1): 23–35. doi:10.1038/nri978. PMID 12511873. S2CID 23185583.
  48. ^ Peters VA, Joesting JJ, Freund GG (August 2013). "IL-1 receptor 2 (IL-1R2) and its role in immune regulation". Brain, Behavior, and Immunity. 32: 1–8. doi:10.1016/j.bbi.2012.11.006. PMC 3610842. PMID 23195532.
  49. ^ Muntjewerff EM, Meesters LD, van den Bogaart G (8 July 2020). "Antigen Cross-Presentation by Macrophages". Frontiers in Immunology. 11: 1276. doi:10.3389/fimmu.2020.01276. PMC 7360722. PMID 32733446.
  50. ^ Xu W, Banchereau J (January 2014). "The antigen presenting cells instruct plasma cell differentiation". Frontiers in Immunology. 4: 504. doi:10.3389/fimmu.2013.00504. PMC 3880943. PMID 24432021.
  51. ^ Cotran RS, Kumar V, Collins T (1999). Robbins Pathologic Basis of Disease. Philadelphia: W.B Saunders Company. ISBN 978-0-7216-7335-6.
  52. ^ "The lymphocyte story". New Scientist (1605). Retrieved 13 September 2007.
  53. ^ a b c d Hesketh M, Sahin KB, West ZE, Murray RZ (July 2017). "Macrophage Phenotypes Regulate Scar Formation and Chronic Wound Healing". International Journal of Molecular Sciences. 18 (7): 1545. doi:10.3390/ijms18071545. PMC 5536033. PMID 28714933.
  54. ^ Galdiero MR, Garlanda C, Jaillon S, Marone G, Mantovani A (July 2013). "Tumor associated macrophages and neutrophils in tumor progression". Journal of Cellular Physiology. 228 (7): 1404–1412. doi:10.1002/jcp.24260. PMID 23065796. S2CID 41189572.
  55. ^ Hotamisligil GS (April 2010). "Endoplasmic reticulum stress and atherosclerosis". Nature Medicine. 16 (4): 396–399. doi:10.1038/nm0410-396. PMC 2897068. PMID 20376052.
  56. ^ Oh J, Riek AE, Weng S, Petty M, Kim D, Colonna M, et al. (April 2012). "Endoplasmic reticulum stress controls M2 macrophage differentiation and foam cell formation". The Journal of Biological Chemistry. 287 (15): 11629–11641. doi:10.1074/jbc.M111.338673. PMC 3320912. PMID 22356914.
  57. ^ Krippendorf BB, Riley DA (January 1993). "Distinguishing unloading- versus reloading-induced changes in rat soleus muscle". Muscle & Nerve. 16 (1): 99–108. doi:10.1002/mus.880160116. PMID 8423838. S2CID 23012375.
  58. ^ a b c St Pierre BA, Tidball JG (July 1994). "Differential response of macrophage subpopulations to soleus muscle reloading after rat hindlimb suspension". Journal of Applied Physiology. 77 (1): 290–297. doi:10.1152/jappl.1994.77.1.290. PMID 7961247.
  59. ^ Tidball JG, Berchenko E, Frenette J (April 1999). "Macrophage invasion does not contribute to muscle membrane injury during inflammation". Journal of Leukocyte Biology. 65 (4): 492–498. doi:10.1002/jlb.65.4.492. PMID 10204578. S2CID 23315528.
  60. ^ a b Schiaffino S, Partridge T (2008). Skeletal Muscle Repair and Regeneration. Advances in Muscle Research. Vol. 3.
  61. ^ Bréchot N, Gomez E, Bignon M, Khallou-Laschet J, Dussiot M, Cazes A, et al. (2008). "Modulation of macrophage activation state protects tissue from necrosis during critical limb ischemia in thrombospondin-1-deficient mice". PLOS ONE. 3 (12): e3950. Bibcode:2008PLoSO...3.3950B. doi:10.1371/journal.pone.0003950. PMC 2597179. PMID 19079608.
  62. ^ a b de la Torre J., Sholar A. (2006). Wound healing: Chronic wounds. Emedicine.com. Accessed 20 January 2008.
  63. ^ "The phases of cutaneous wound healing" (PDF). Expert Reviews in Molecular Medicine. 5. Cambridge University Press. 21 March 2003. Archived from the original (PDF) on 17 December 2008.
  64. ^ Lorenz HP, Longaker MT (2003). "Wounds: biology, pathology, and management." (PDF). In Li M, Norton JA, Bollinger RR, Chang AE, Lowry SF, Mulvihill SJ, Pass HI, Thompson RW (eds.). Essential practice of surgery. New York, NY: Springer. pp. 77–88. ISBN 978-0-387-22744-3. Archived from the original (PDF) on 31 October 2005.
  65. ^ Swirski FK, Nahrendorf M, Etzrodt M, Wildgruber M, Cortez-Retamozo V, Panizzi P, et al. (July 2009). "Identification of splenic reservoir monocytes and their deployment to inflammatory sites". Science. 325 (5940): 612–616. Bibcode:2009Sci...325..612S. doi:10.1126/science.1175202. PMC 2803111. PMID 19644120.
  66. ^ Jia T, Pamer EG (July 2009). "Immunology. Dispensable but not irrelevant". Science. 325 (5940): 549–550. Bibcode:2009Sci...325..549J. doi:10.1126/science.1178329. PMC 2917045. PMID 19644100.
  67. ^ Deodhar AK, Rana RE (1997). "Surgical physiology of wound healing: a review". Journal of Postgraduate Medicine. 43 (2): 52–56. PMID 10740722.
  68. ^ Rosenberg L., de la Torre J. (2006). Wound Healing, Growth Factors. Emedicine.com. Accessed 20 January 2008.
  69. ^ Newton PM, Watson JA, Wolowacz RG, Wood EJ (August 2004). "Macrophages restrain contraction of an in vitro wound healing model". Inflammation. 28 (4): 207–214. doi:10.1023/B:IFLA.0000049045.41784.59. PMID 15673162. S2CID 9612298.
  70. ^ Greenhalgh DG (September 1998). "The role of apoptosis in wound healing". The International Journal of Biochemistry & Cell Biology. 30 (9): 1019–1030. doi:10.1016/S1357-2725(98)00058-2. PMID 9785465.
  71. ^ Stashak TS, Farstvedt E, Othic A (June 2004). "Update on wound dressings: Indications and best use". Clinical Techniques in Equine Practice. 3 (2): 148–163. doi:10.1053/j.ctep.2004.08.006.
  72. ^ a b Souppouris A (23 May 2013). "Scientists identify cell that could hold the secret to limb regeneration". the verge.com. Researchers have identified a cell that aids limb regrowth in Salamanders. Macrophages are a type of repairing cell that devour dead cells and pathogens, and trigger other immune cells to respond to pathogens.
  73. ^ a b Godwin JW, Pinto AR, Rosenthal NA (June 2013). "Macrophages are required for adult salamander limb regeneration". Proceedings of the National Academy of Sciences of the United States of America. 110 (23): 9415–9420. Bibcode:2013PNAS..110.9415G. doi:10.1073/pnas.1300290110. PMC 3677454. PMID 23690624.
  74. ^ Mishima Y (October 1967). "Lysosomes in malanin phagocytosis and synthesis". Nature. 216 (5110): 67. Bibcode:1967Natur.216...67M. doi:10.1038/216067a0. PMID 6050674. S2CID 4285140.
  75. ^ Mishima Y (January 1966). "Cellular and subcellular differentiation of melanin phagocytosis and synthesis by lysosomal and melanosomal activity". The Journal of Investigative Dermatology. 46 (1): 70–75. doi:10.1038/jid.1966.11. PMID 5905254.
  76. ^ Baranska A, Shawket A, Jouve M, Baratin M, Malosse C, Voluzan O, et al. (April 2018). "Unveiling skin macrophage dynamics explains both tattoo persistence and strenuous removal". The Journal of Experimental Medicine. 215 (4): 1115–1133. doi:10.1084/jem.20171608. PMC 5881467. PMID 29511065.
  77. ^ Okabe Y, Medzhitov R (May 2014). "Tissue-specific signals control reversible program of localization and functional polarization of macrophages". Cell. 157 (4): 832–844. doi:10.1016/j.cell.2014.04.016. PMC 4137874. PMID 24792964.
  78. ^ Gosselin D, Link VM, Romanoski CE, Fonseca GJ, Eichenfield DZ, Spann NJ, et al. (December 2014). "Environment drives selection and function of enhancers controlling tissue-specific macrophage identities". Cell. 159 (6): 1327–1340. doi:10.1016/j.cell.2014.11.023. PMC 4364385. PMID 25480297.
  79. ^ Muller PA, Koscsó B, Rajani GM, Stevanovic K, Berres ML, Hashimoto D, et al. (July 2014). "Crosstalk between muscularis macrophages and enteric neurons regulates gastrointestinal motility". Cell. 158 (2): 300–313. doi:10.1016/j.cell.2014.04.050. PMC 4149228. PMID 25036630.
  80. ^ Uderhardt S, Martins AJ, Tsang JS, Lämmermann T, Germain RN (April 2019). "Resident Macrophages Cloak Tissue Microlesions to Prevent Neutrophil-Driven Inflammatory Damage". Cell. 177 (3): 541–555.e17. doi:10.1016/j.cell.2019.02.028. PMC 6474841. PMID 30955887.
  81. ^ Kolter J, Kierdorf K, Henneke P (January 2020). "Origin and Differentiation of Nerve-Associated Macrophages". Journal of Immunology. 204 (2): 271–279. doi:10.4049/jimmunol.1901077. PMID 31907269. S2CID 210043405.
  82. ^ Wolf AJ, Underhill DM (2014). "Phagocytosis". Macrophages: Biology and Role in the Pathology of Diseases. Springer New York. pp. 91–109. doi:10.1007/978-1-4939-1311-4_5. ISBN 978-1-4939-1310-7.
  83. ^ Herb M, Schramm M (February 2021). "Functions of ROS in Macrophages and Antimicrobial Immunity". Antioxidants. 10 (2): 313. doi:10.3390/antiox10020313. PMC 7923022. PMID 33669824.
  84. ^ Weiss G, Schaible UE (March 2015). "Macrophage defense mechanisms against intracellular bacteria". Immunological Reviews. 264 (1): 182–203. doi:10.1111/imr.12266. PMC 4368383. PMID 25703560.
  85. ^ Ryan KJ, Ray CG, eds. (2004). Sherris Medical Microbiology (4th ed.). McGraw Hill. ISBN 978-0-8385-8529-0.
  86. ^ Dupuis-Maguiraga L, Noret M, Brun S, Le Grand R, Gras G, Roques P (2012). "Chikungunya disease: infection-associated markers from the acute to the chronic phase of arbovirus-induced arthralgia". PLOS Neglected Tropical Diseases. 6 (3): e1446. doi:10.1371/journal.pntd.0001446. PMC 3313943. PMID 22479654.
  87. ^ Lucas AD, Greaves DR (November 2001). "Atherosclerosis: role of chemokines and macrophages". Expert Reviews in Molecular Medicine. 3 (25): 1–18. doi:10.1017/S1462399401003696. PMID 14585150. S2CID 8952545.
  88. ^ Frantz S, Nahrendorf M (May 2014). "Cardiac macrophages and their role in ischaemic heart disease". Cardiovascular Research. 102 (2): 240–248. doi:10.1093/cvr/cvu025. PMC 3989449. PMID 24501331.
  89. ^ Grune J, Lewis AJ, Yamazoe M, Hulsmans M, Rohde D, Xiao L, et al. (July 2022). "Neutrophils incite and macrophages avert electrical storm after myocardial infarction". Nature Cardiovascular Research. 1 (7): 649–664. doi:10.1038/s44161-022-00094-w. PMC 9410341. PMID 36034743. S2CID 250475623.
  90. ^ Bol SM, Cobos-Jiménez V, Kootstra NA, van't Wout AB (February 2011). "Macrophage". Future Virology. 6 (2): 187–208. doi:10.2217/fvl.10.93.
  91. ^ Koppensteiner H, Brack-Werner R, Schindler M (October 2012). "Macrophages and their relevance in Human Immunodeficiency Virus Type I infection". Retrovirology. 9 (1): 82. doi:10.1186/1742-4690-9-82. PMC 3484033. PMID 23035819.
  92. ^ Qian BZ, Pollard JW (April 2010). "Macrophage diversity enhances tumor progression and metastasis". Cell. 141 (1): 39–51. doi:10.1016/j.cell.2010.03.014. PMC 4994190. PMID 20371344.
  93. ^ a b Engblom C, Pfirschke C, Pittet MJ (July 2016). "The role of myeloid cells in cancer therapies". Nature Reviews. Cancer. 16 (7): 447–462. doi:10.1038/nrc.2016.54. PMID 27339708. S2CID 21924175.
  94. ^ Stix G (July 2007). "A malignant flame. Understanding chronic inflammation, which contributes to heart disease, Alzheimer's and a variety of other ailments, may be a key to unlocking the mysteries of cancer". Scientific American. 297 (1): 60–67. Bibcode:2007SciAm.297a..60S. doi:10.1038/scientificamerican0707-60. PMID 17695843.
  95. ^ Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, et al. (December 2006). "Macrophages regulate the angiogenic switch in a mouse model of breast cancer". Cancer Research. 66 (23): 11238–11246. doi:10.1158/0008-5472.can-06-1278. PMID 17114237. S2CID 12722658.
  96. ^ Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002; 196:254–65.
  97. ^ de Groot AE (July 2018). "In vitro human tumor-associated macrophage model implicates macrophage proliferation as a mechanism for maintaining tumor-associated macrophage populations". Cancer Research. 78 (13 Supplement): 4060. doi:10.1158/1538-7445.AM2018-4060. S2CID 80769044.
  98. ^ Lin EY, Nguyen AV, Russell RG, Pollard JW (March 2001). "Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy". The Journal of Experimental Medicine. 193 (6): 727–740. doi:10.1084/jem.193.6.727. PMC 2193412. PMID 11257139.
  99. ^ Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, et al. (June 2011). "CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis". Nature. 475 (7355): 222–225. doi:10.1038/nature10138. PMC 3208506. PMID 21654748.
  100. ^ Cortez-Retamozo V, Etzrodt M, Newton A, Ryan R, Pucci F, Sio SW, et al. (February 2013). "Angiotensin II drives the production of tumor-promoting macrophages". Immunity. 38 (2): 296–308. doi:10.1016/j.immuni.2012.10.015. PMC 3582771. PMID 23333075.
  101. ^ Pucci F, Garris C, Lai CP, Newton A, Pfirschke C, Engblom C, et al. (April 2016). "SCS macrophages suppress melanoma by restricting tumor-derived vesicle-B cell interactions". Science. 352 (6282): 242–246. Bibcode:2016Sci...352..242P. doi:10.1126/science.aaf1328. PMC 4960636. PMID 26989197.
  102. ^ Mantovani A, Allavena P (April 2015). "The interaction of anticancer therapies with tumor-associated macrophages". The Journal of Experimental Medicine. 212 (4): 435–445. doi:10.1084/jem.20150295. PMC 4387285. PMID 25753580.
  103. ^ De Palma M, Lewis CE (March 2013). "Macrophage regulation of tumor responses to anticancer therapies". Cancer Cell. 23 (3): 277–286. doi:10.1016/j.ccr.2013.02.013. PMID 23518347.
  104. ^ Miller MA, Zheng YR, Gadde S, Pfirschke C, Zope H, Engblom C, et al. (October 2015). "Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug". Nature Communications. 6: 8692. Bibcode:2015NatCo...6.8692M. doi:10.1038/ncomms9692. PMC 4711745. PMID 26503691.
  105. ^ Klug F, Prakash H, Huber PE, Seibel T, Bender N, Halama N, et al. (November 2013). "Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy". Cancer Cell. 24 (5): 589–602. doi:10.1016/j.ccr.2013.09.014. PMID 24209604.
  106. ^ Ruffell B, Chang-Strachan D, Chan V, Rosenbusch A, Ho CM, Pryer N, et al. (November 2014). "Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells". Cancer Cell. 26 (5): 623–637. doi:10.1016/j.ccell.2014.09.006. PMC 4254570. PMID 25446896.
  107. ^ DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, et al. (June 2011). "Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy". Cancer Discovery. 1 (1): 54–67. doi:10.1158/2159-8274.CD-10-0028. PMC 3203524. PMID 22039576.
  108. ^ Shiao SL, Ruffell B, DeNardo DG, Faddegon BA, Park CC, Coussens LM (May 2015). "TH2-Polarized CD4(+) T Cells and Macrophages Limit Efficacy of Radiotherapy". Cancer Immunology Research. 3 (5): 518–525. doi:10.1158/2326-6066.CIR-14-0232. PMC 4420686. PMID 25716473.
  109. ^ Kozin SV, Kamoun WS, Huang Y, Dawson MR, Jain RK, Duda DG (July 2010). "Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation". Cancer Research. 70 (14): 5679–5685. doi:10.1158/0008-5472.CAN-09-4446. PMC 2918387. PMID 20631066.
  110. ^ Arlauckas SP, Garris CS, Kohler RH, Kitaoka M, Cuccarese MF, Yang KS, et al. (May 2017). "In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy". Science Translational Medicine. 9 (389): eaal3604. doi:10.1126/scitranslmed.aal3604. PMC 5734617. PMID 28490665.
  111. ^ Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, et al. (September 2014). "CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models". Cancer Research. 74 (18): 5057–5069. doi:10.1158/0008-5472.CAN-13-3723. PMC 4182950. PMID 25082815.
  112. ^ Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, et al. (June 2014). "Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy". Cancer Cell. 25 (6): 846–859. doi:10.1016/j.ccr.2014.05.016. PMID 24898549.
  113. ^ Ruffell B, Coussens LM (April 2015). "Macrophages and therapeutic resistance in cancer". Cancer Cell. 27 (4): 462–472. doi:10.1016/j.ccell.2015.02.015. PMC 4400235. PMID 25858805.
  114. ^ Sharma N, Vacher J, Allison JP (May 2019). "TLR1/2 ligand enhances antitumor efficacy of CTLA-4 blockade by increasing intratumoral Treg depletion". Proceedings of the National Academy of Sciences of the United States of America. 116 (21): 10453–10462. Bibcode:2019PNAS..11610453S. doi:10.1073/pnas.1819004116. PMC 6534983. PMID 31076558.
  115. ^ Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is associated with macrophage accumulation in adipose tissue" Journal of Clinical Investigation 2003; 112:1796–808.
  116. ^ Guilherme A, Henriques F, Bedard AH, Czech MP (April 2019). "Molecular pathways linking adipose innervation to insulin action in obesity and diabetes mellitus". Nature Reviews. Endocrinology. 15 (4): 207–225. doi:10.1038/s41574-019-0165-y. PMC 7073451. PMID 30733616.
  117. ^ Petkevicius K, Bidault G, Virtue S, Newland SA, Dale M, Dugourd A, et al. (June 2021). "Macrophage beta2-adrenergic receptor is dispensable for the adipose tissue inflammation and function". Molecular Metabolism. 48: 101220. doi:10.1016/j.molmet.2021.101220. PMC 8086137. PMID 33774223.
  118. ^ Bolus WR, Gutierrez DA, Kennedy AJ, Anderson-Baucum EK, Hasty AH (October 2015). "CCR2 deficiency leads to increased eosinophils, alternative macrophage activation, and type 2 cytokine expression in adipose tissue". Journal of Leukocyte Biology. 98 (4): 467–477. doi:10.1189/jlb.3HI0115-018R. PMC 4763864. PMID 25934927.
  119. ^ Boutens L, Stienstra R (May 2016). "Adipose tissue macrophages: going off track during obesity". Diabetologia. 59 (5): 879–894. doi:10.1007/s00125-016-3904-9. PMC 4826424. PMID 26940592.
  120. ^ Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, Faloia E, et al. (November 2005). "Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans". Journal of Lipid Research. 46 (11): 2347–2355. doi:10.1194/jlr.M500294-JLR200. PMID 16150820.
  121. ^ Kühl AA, Erben U, Kredel LI, Siegmund B (7 December 2015). "Diversity of Intestinal Macrophages in Inflammatory Bowel Diseases". Frontiers in Immunology. 6: 613. doi:10.3389/fimmu.2015.00613. PMC 4670857. PMID 26697009.
  122. ^ a b c Smythies LE, Sellers M, Clements RH, Mosteller-Barnum M, Meng G, Benjamin WH, et al. (January 2005). "Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity". The Journal of Clinical Investigation. 115 (1): 66–75. doi:10.1172/JCI19229. PMC 539188. PMID 15630445.
  123. ^ a b Mowat AM, Bain CC (2011). "Mucosal macrophages in intestinal homeostasis and inflammation". Journal of Innate Immunity. 3 (6): 550–564. doi:10.1159/000329099. PMC 3224516. PMID 22025201.
  124. ^ Bain CC, Mowat AM (July 2014). "Macrophages in intestinal homeostasis and inflammation". Immunological Reviews. 260 (1): 102–117. doi:10.1111/imr.12192. PMC 4141699. PMID 24942685.
  125. ^ Weiss G (January 2023). "Macrophage vesicles starve bacteria of iron". Nature Metabolism. 5 (1): 10–12. doi:10.1038/s42255-022-00719-1. PMID 36658401. S2CID 256030791.
  126. ^ Epelman S, Lavine KJ, Randolph GJ (July 2014). "Origin and functions of tissue macrophages". Immunity. 41 (1): 21–35. doi:10.1016/j.immuni.2014.06.013. PMC 4470379. PMID 25035951.
  127. ^ Mass E, Lachmann N (September 2021). "From macrophage biology to macrophage-based cellular immunotherapies". Gene Therapy. 28 (9): 473–476. doi:10.1038/s41434-021-00221-5. PMC 8455330. PMID 33542457.
  128. ^ Epelman S, Lavine KJ, Randolph GJ (July 2014). "Origin and functions of tissue macrophages". Immunity. 41 (1): 21–35. doi:10.1016/j.immuni.2014.06.013. PMC 4470379. PMID 25035951.
  129. ^ Italiani P, Boraschi D (August 2015). "New Insights Into Tissue Macrophages: From Their Origin to the Development of Memory". Immune Network. 15 (4): 167–176. doi:10.4110/in.2015.15.4.167. PMC 4553254. PMID 26330802.
  130. ^ Lazarov T, Juarez-Carreño S, Cox N, Geissmann F (June 2023). "Physiology and diseases of tissue-resident macrophages". Nature. 618 (7966): 698–707. Bibcode:2023Natur.618..698L. doi:10.1038/s41586-023-06002-x. PMC 10649266. PMID 37344646.
Wikimedia Commons has media related to Macrophages.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Macrophage&oldid=1252344836"